What Dr. Max does

Dr. Max Group is one of Europe's largest pharmacy retail and pharmaceutical distribution networks, operating nearly 3,000 pharmacies across six core markets — Czech Republic (488), Slovakia (356), Poland (543), Romania (866), Serbia (320), and Italy (210+ after the 2023 Neo Apotek acquisition) — with broader wholesale and marketing & sales operations reaching 17 to 18 European countries. The company runs an integrated three-pillar business model: pharmacy retail (brick-and-mortar plus e-shop platforms with 40%+ market share in Czech Republic and Slovakia per IQVIA), pharmaceutical wholesale distribution (ViaPharma, MagnaPharm, MEDICAL GROUP SK), and private-label manufacturing through Dr. Max Pharma, which manages nearly 300 drug registrations and approximately 1,300 SKUs and became the largest pharmaceutical producer in the Czech Republic in 2023. Technology investments include Autonomous Mobile Robots in the Bucharest warehouse (Supply Chain Excellence Awards 2023 winner), ROWA robotic dispensing in pharmacies, a new 14,000 m2 centralized distribution center in Telgate (Italy) with planned automation, and a 10.6 million-member loyalty benefit program.

The company serves general consumers and patients seeking pharmaceutical products, OTC medicines, wellness offerings, and expanded in-pharmacy services (vaccinations, health screenings, chronic disease support) through formats ranging from standard pharmacies to hyper-pharmacies (Super Dr.Max in Serbia, hyper-pharmacies in Romania) and self-service dispensing boxes. A secondary B2B segment provides wholesale distribution and marketing & sales services to pharmaceutical companies in markets including Hungary and Bulgaria. Revenue is generated primarily through retail transactions, with additional streams from wholesale distribution, e-commerce, and private-label/licensing; in 2023, reported revenue was €4.6 billion, representing 20% year-over-year growth, with e-commerce revenue up 55% and Dr. Max Pharma revenue up 34%.

Dr. Max is wholly owned by Penta Investments, a Central and Eastern European private investment group whose portfolio companies employ more than 43,000 people across healthcare, financial services, retail, manufacturing, media, and real estate. Capital structure diversification in 2022–2023 included a EUR 940 million refinancing with a 14-bank syndicate and a CZK 5 billion oversubscribed corporate bond issuance on the Czech capital market in December 2023. The group operates with a dedicated leadership team spanning CEO (Leonardo Ferrandino), CFO, Chief Supply Chain Officer, Chief Commercial Officer, Chief Marketing & Customer Officer, Chief Product Officer, and Group Chief IT Officer, plus country-level CEOs in each core market.

Name

Dr. Max

Legal name

Dr. Max BDC, s.r.o.

Website

https://drmax.eu

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Dr. Max Group operates nearly 3,000 pharmacies across six European countries plus wholesale distribution and private-label pharmaceutical manufacturing, serving millions of consumers and pharmaceutical-company B2B customers under Penta Investments ownership.

Ownership category

akta.pro rank

Product category

Retail Pharmacy

NAICS

Pharmacies and Drug Retailers (45611), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Retail-Drug Stores And Proprietary Stores (5912), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Pharmacy-Led Health & Wellness Discount Retail (CRAEAHAD)

akta.pro secondary industries

Pharmacy & Health Essentials Delivery (CRAFAFAI), Pharmacy & Health Clinic Store-in-Store (CRAGAHAK)

Keywords

• Retail pharmacy
• Pharmaceutical distribution
• Prescription medications
• Health products
• Online pharmacy

Headquarters

HQ city

Prague

HQ country

Czechia

HQ region

Europe

Offices16 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Retail Pharmacy Operations: Revenue from sale of pharmaceutical products through owned pharmacy network across 6 European countries (Czech Republic, Slovakia, Poland, Romania, Serbia, Italy) with nearly 3,000 pharmacies
2. Wholesale Distribution: Pharmaceutical wholesale division operating across Europe, including acquisition of MEDICAL GROUP SK a.s. in Slovakia and ViaPharma distribution operations
3. Marketing & Sales Division: Fast-growing marketing and sales division active in Hungarian and Bulgarian markets, providing services for pharmaceutical companies
4. Private Label Products (Dr. Max Pharma): Own brand pharmaceutical products including Rx and OTC generic medicines, food supplements, cosmetics, and medical devices; 119 new non-medicinal products introduced in 2023; 84 million products sold across markets in 2023; 34% revenue growth in 2023
5. E-commerce: Online pharmacy sales through e-shop platforms with 55% YoY increase in e-commerce revenue in 2023; leading online position in Czech Republic and Slovakia with over 40% market share

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

Core offering

Dr. Max operates a chain of retail pharmacies across Central and Eastern Europe, dispensing prescription and over-the-counter medications, health and wellness products, and pharmacy services. The company complements its physical pharmacy network with e-shop (online) pharmacy platforms and operates pharmaceutical wholesale distribution to serve retail and institutional customers across the region.

Product overview

Dr. Max Group operates as a multi-format pharmacy retail and digital healthcare platform with three interconnected streams: pharmacy retail (brick-and-mortar and e-shop pharmacies), pharmaceutical distribution (wholesale via ViaPharma and MagnaPharm), and private label manufacturing (Dr. Max Pharma producing Nuance Organic, Bebelo, and other brands). The core offering centers on nearly 3,000 pharmacies across 6 European countries, supplemented by online pharmacy services with +40% market share in Czech Republic and Slovakia, wholesale distribution, and proprietary health/wellness product lines. The company also operates hyper-pharmacy formats and dispensing boxes for omnichannel customer access.

Differentiator

Problem solved

Functional benefit

Brands

• Dr. Max Pharma: Private label pharmaceutical manufacturing division producing licensed (Rx and OTC generic medicines) and non-licensed products including food supplements, cosmetics, and medical devices. Manages portfolio of nearly 1,300 SKUs and is the largest pharmaceutical producer in the Czech Republic.
• MagnaPharm
• ViaPharma
• Nuance
• Bebelo
• Super Dr.Max
• Neo Apotek
• Respiro

Products and services

• Retail Pharmacy Network Network of brick-and-mortar pharmacies selling prescription and over-the-counter medications, health and wellness products, and offering pharmacy services to consumers across Central and Eastern Europe.
• Online Pharmacy (E-shop) E-commerce platform for ordering prescription and over-the-counter medications, health products, and pharmacy services online for delivery or pickup.
• Pharmaceutical Wholesale Distribution Wholesale distribution of pharmaceutical products serving retail pharmacies and institutional customers across Central and Eastern Europe.

Quantifiable outcome

• 55% YoY increase in e-commerce revenue in 2023
• +6 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Nine partnerships are on record, tiered core, minor and major.

• Dr. Max PharmacoreStrategic or Co-development PartnerWholly-owned subsidiary established in 2011 producing private label products including licensed (Rx and OTC generic medicines) and non-licensed products (food supplements, cosmetics, medical devices). Manages nearly 300 drug registrations with approximately 1,300 SKUs. Became largest pharmaceutical producer in Czech Republic in 2023.
• Košík.czminorChannel Partner/ Reseller/ DistributorCzech e-commerce marketplace partnership for wider product availability. Dr. Max products are now accessible through the Košík.cz platform with qualified staff preparing orders for courier delivery.
• Křižovatka (Crossroad) FoundationminorStrategic or Co-development PartnerCorporate philanthropy partnership for SIDS prevention. Through selected maternity hospitals (including Roudnice maternity hospital belonging to Penta Hospitals chain), Dr. Max provides 200 breathing monitors to mothers who cannot afford to purchase equipment.
• Apotheke SlovakiamajorStrategic or Co-development PartnerBusiness agreement to acquire 47 pharmacies of the Apotheke Slovakia brand, subject to antimonopoly office approval. Transaction expected to close the following year with pharmacies to be rebranded under Dr. Max.
• Neo Apotek S.p.A.majorStrategic or Co-development PartnerStrategic acquisition adding over 130 pharmacies to Dr. Max Italy, bringing total to over 210 pharmacies. Neo Apotek had made substantial investments in growth and the central role of pharmacists. Acquisition supported by advisors EY, Shearman & Sterling, and AK Evan.
• MEDICAL GROUP SK a.s.majorStrategic or Co-development PartnerDistribution company acquired by Dr. Max Slovakia to strengthen market position in wholesale distributors of medicines and medical devices. Acquisition audit prepared with Ernst & Young law firm Skubla & Partners.
• Prologis Park BratislavaminorOthersCommercial real estate partnership for new warehouse facility in Prologis Park Bratislava to support e-shop operations and modern infrastructure.
• EY, Shearman & Sterling, AK EvancoreImplementation/ SI/ Consulting PartnerAdvisors for Neo Apotek S.p.A. acquisition. Dr. Max assisted by EY, Shearman & Sterling and AK Evan; Neo Apotek assisted by Rotschild & Co., Studio Legale Gattai and Banca Profilo.
• Dentons Bratislava, AK Evan, White & Case PrahacoreImplementation/ SI/ Consulting PartnerLegal advisors for comprehensive refinancing: Dentons Bratislava led by Patricia Gossanyiova and AK Evan led by Jan Evan for borrower side; White & Case Praha led by Tomas Jine for banks.

Scale indicators22 records

Recent moves22 records

Expansion highlights7 records

Direct peers

• Celesio (McKesson Europe): Celesio operates Lloyds Pharmacy and European wholesale distribution, serving millions of customers across pharmacy retail and B2B pharma services. Closely comparable to Dr. Max's integrated retail-wholesale model and pan-European footprint.
• Phoenix Group: Phoenix Group is Europe's largest pharmacy retailer, operating over 17,000 pharmacies across 17 European countries with parallel wholesale and pharma services. Direct comparable to Dr. Max in multi-country European pharmacy consolidation, vertically integrated distribution, and private label strategy.
• Alliance Healthcare (Walgreens Boots Alliance): Alliance Healthcare is the European pharmaceutical wholesale and distribution arm of WBA, serving independent pharmacies across Europe. Directly comparable to Dr. Max's ViaPharma and MagnaPharm wholesale distribution operations.

Emerging players

• DocMorris (Zur Rose Group): DocMorris operates one of Europe's largest e-pharmacy platforms and is expanding into prescription drug delivery. A relevant peer for Dr. Max's digital pharmacy and home delivery business, especially across the DACH and Benelux corridors.
• Shop Apotheke: Shop Apotheke is one of Europe's leading online pharmacies, operating across Germany, Netherlands, Austria, and other EU markets. Directly comparable to Dr. Max's e-commerce pharmacy business, particularly the +40% market share position Dr. Max holds in CZ/SK.
• Mediq: Mediq is a European healthcare distributor and homecare provider operating across pharmacy supply, medical devices, and home delivery. Adjacent peer given overlapping wholesale and home delivery of medical products, especially in Benelux and CEE-adjacent markets.

Broad incumbents

• Walgreens Boots Alliance: WBA is a global pharmacy and retail giant with over 13,000 stores in the US, UK (Boots), and other markets. While primarily US-anchored, it competes in European pharmacy through Boots and is the global benchmark for vertically integrated pharmacy retail.
• A.S. Watson Group: A.S. Watson is the world's largest health and beauty retailer with ~16,800 stores including Watsons, Superdrug, and Savers/Perfumerias. A broad incumbent with overlapping pharmacy and health retail categories across multiple geographies.
• dm-drogerie markt: dm operates ~4,000 drugstore stores across 13 European countries, with adjacent OTC and health product categories. Comparable in multi-country European footprint and as a private-label-led health and personal care retailer.
• Rossmann: Rossmann is one of Europe's largest drugstore chains with ~4,400 stores in Germany and other European markets, with strong private label and OTC focus. Comparable as a drugstore/pharmacy hybrid operating across European geographies with private label scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/DrMax
• LinkedInlinkedin.com/company/dr-max

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dr. Max